The project is estimated to run from late Q4 2023 until Q1 2026 and the platform is aimed to shorten time for drug development workflows. The project will run in a ramp-up phase during 2024 and the vast majority of the project will be carried out and invoiced during 2025.
“This agreement is a milestone for the Group and it’s our largest project to date. It also shows the strength in Biosero’s offering for laboratory automation solutions and we expect to shorten current timelines for drug development through automation”, says Maria Forss, President and CEO, BICO.
BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD
Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for a total value of 28 MUSD to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects
You may also like
Trending Articles
You may also like
Research & Development
OSE Immunotherapeutics gets positive IDMC recommendation to continue Phase III trial of Tedopi for lung cancer
The Independent Data Monitoring Committee has endorsed the ongoing pivotal Phase III ARTEMIA study evaluating Tedopi in HLA-A2–positive metastatic non-small cell lung cancer
Research & Development
American Cancer Society expands ACS ACTS programme to boost equity in cancer clinical trials nationwide
Leveraging trained specialists and AI-powered trial matching, the ACS ACTS programme helps patients, caregivers and providers navigate clinical trial options while addressing barriers to participation